Selecta spreads tolerance

Having been founded in 2008 to use its nanoparticles to stoke the immune system for vaccine applications, Selecta Biosciences Inc. is extending the platform with a 180˚ turn on that principle, using the same particles to cause immune tolerance by suppressing the generation of neutralizing antibodies that hamper efficacy for many biologics.

With its first program in Phase I, Selecta has now elucidated both the mechanism involved and the delivery requirements for its new approach, and is lining up a series of preclinical programs to test the particles with a range of modalities, including protein therapeutics, complex antibody constructs and gene therapies...